Gilbert Benavidez, Boston University School of Public Health policy analyst, discussed the value-based practices incorporated by CVS and Express Scripts in two recent blog posts on The Incidental Economist.
Benavidez in his write up notes CVS utilizes value-based management strategies by nixing drugs from its formulary in favor of cheaper drugs with equal clinical effectiveness.
And value-based thinking on behalf of CVS isn’t entirely new, Benavidez writes, adding the PBM recently announced it was working with the Institute of Clinical and Economic Review and an independent advisory board to develop new plan designs.
Express Scripts is also taking a similar path, Benavidez says, after cutting Amgen’s Repatha and replacing it Sanofi and Regeneron’s Praluent.
To read the first part of his full post, click here.